BUZZ-Clearside Biomedical plunges after filing for bankruptcy

Reuters11-24

BUZZ-<a href="https://laohu8.com/S/CLSD">Clearside Biomedical</a> plunges after filing for bankruptcy

** Shares of drug developer Clearside Biomedical CLSD.O slide 51.8% to $1.37 in premarket

** Co files for Chapter 11 bankruptcy protection in a U.S. court, estimates assets in range of $1 mln to $10 mln and liabilities between $50 mln and $100 mln, as per filing

** Co reported a loss of $1.14 per share in the quarter ended September 30, lesser than $1.54 per share a year ago

** In its quarterly results filing on November 14, co raised going concerns, saying it may not be able to continue without additional funding or strategic transaction

** Co has been exploring a sale, licensing or partnerships to advance its drug pipeline and SCS platform - a drug delivery system - since July

** CLSD stock down 80.9% YTD, as of last close

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585469228?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 19:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585469228","market":"us","top_or_hot":-1,"title":"BUZZ-Clearside Biomedical plunges after filing for bankruptcy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/CLSD\">Clearside Biomedical</a> plunges after filing for bankruptcy</title></head><body><p>** Shares of drug developer Clearside Biomedical <span>CLSD.O</span> slide 51.8% to $1.37 in premarket</p><p>** Co files for <span>Chapter 11 bankruptcy</span> protection in a U.S. court, estimates assets in range of $1 mln to $10 mln and liabilities between $50 mln and $100 mln, as per filing</p><p>** Co reported a loss of $1.14 per share in the quarter ended September 30, lesser than $1.54 per share a year ago</p><p>** In its quarterly results filing on November 14, co raised going concerns, saying it may not be able to continue without additional funding or strategic transaction</p><p>** Co has been exploring a sale, licensing or partnerships to advance its drug pipeline and SCS platform - a drug delivery system - since July</p><p>** CLSD stock down 80.9% YTD, as of last close</p><p> (Reporting by Tharuniyaa Lakshmi in Bengaluru)</p><p> ((tharuniyaa@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Clearside Biomedical plunges after filing for bankruptcy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Clearside Biomedical plunges after filing for bankruptcy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 19:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/CLSD\">Clearside Biomedical</a> plunges after filing for bankruptcy</title></head><body><p>** Shares of drug developer Clearside Biomedical <span>CLSD.O</span> slide 51.8% to $1.37 in premarket</p><p>** Co files for <span>Chapter 11 bankruptcy</span> protection in a U.S. court, estimates assets in range of $1 mln to $10 mln and liabilities between $50 mln and $100 mln, as per filing</p><p>** Co reported a loss of $1.14 per share in the quarter ended September 30, lesser than $1.54 per share a year ago</p><p>** In its quarterly results filing on November 14, co raised going concerns, saying it may not be able to continue without additional funding or strategic transaction</p><p>** Co has been exploring a sale, licensing or partnerships to advance its drug pipeline and SCS platform - a drug delivery system - since July</p><p>** CLSD stock down 80.9% YTD, as of last close</p><p> (Reporting by Tharuniyaa Lakshmi in Bengaluru)</p><p> ((tharuniyaa@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLSD","symbol_name":"Clearside Biomedical Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL6N3X00GE:1","article_id":"2585469228","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585469228","pubTimestamp":1763985215,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Clearside Biomedical plunges after filing for bankruptcy** Shares of drug developer Clearside Biomedical CLSD.O slide 51.8% to $1.37 in premarket** Co files for Chapter 11 bankruptcy protection in a U.S. court, estimates assets in range of $1 mln to $10 mln and liabilities between $50 mln and $100 mln, as per filing** Co reported a loss of $1.14 per share in the quarter ended September 30, lesser than $1.54 per share a year ago** In its quarterly results filing on November 14, co raised going concerns, saying it may not be able to continue without additional funding or strategic transaction** Co has been exploring a sale, licensing or partnerships to advance its drug pipeline and SCS platform - a drug delivery system - since July** CLSD stock down 80.9% YTD, as of last close  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLSD":"Clearside Biomedical Inc.","BK4007":"制药","CLSDQ":"Clearside Biomedical, Inc."},"translate_title":"BUZZ-Clearside Biomedical申请破产后股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLSD":0.9,"CLSDQ":0.9},"content_text":"BUZZ-Clearside Biomedical plunges after filing for bankruptcy** Shares of drug developer Clearside Biomedical CLSD.O slide 51.8% to $1.37 in premarket** Co files for Chapter 11 bankruptcy protection in a U.S. court, estimates assets in range of $1 mln to $10 mln and liabilities between $50 mln and $100 mln, as per filing** Co reported a loss of $1.14 per share in the quarter ended September 30, lesser than $1.54 per share a year ago** In its quarterly results filing on November 14, co raised going concerns, saying it may not be able to continue without additional funding or strategic transaction** Co has been exploring a sale, licensing or partnerships to advance its drug pipeline and SCS platform - a drug delivery system - since July** CLSD stock down 80.9% YTD, as of last close (Reporting by Tharuniyaa Lakshmi in Bengaluru) ((tharuniyaa@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585469228","isCrawlerRequest":true}